Penumbra Executive and Leadership Team

Adam Elsesser, the Chairman & Chief Executive Officer at Penumbra, directs the overarching corporate vision and long-term growth strategy for the organization. Overseeing the development of neurovascular access systems and aspiration-based thrombectomy platforms, the Chairman & Chief Executive Officer ensures alignment between engineering innovation and clinical requirements. This leadership role involves managing international market expansion across North America, Europe, and Asia-Pacific regions. By fostering a culture of rapid product iteration, Adam Elsesser drives the company toward maintaining a competitive edge in the medical device sector. The Chairman & Chief Executive Officer collaborates closely with the Board to secure financial stability while prioritizing the delivery of high-performance tools for neurovascular therapies. Through consistent focus on operational excellence, Elsesser maintains the company's position as a leader in mechanical thrombectomy solutions, ultimately supporting the mission to provide advanced medical care to patients worldwide.

Maggie Yuen, the Chief Financial Officer at Penumbra, manages the fiscal health and capital allocation strategies necessary for sustaining large-scale medical device manufacturing. Overseeing financial reporting, budgeting, and investor relations, the Chief Financial Officer ensures the company maintains the liquidity required for continuous research and development. This leadership role involves analyzing global market trends to optimize resource distribution across international operations. By implementing rigorous financial controls, Maggie Yuen supports the scaling of production for the Neuron and Penumbra System product lines. The Chief Financial Officer works alongside executive leadership to evaluate potential growth opportunities and mitigate risks associated with the complex regulatory environments of the medical industry. Through precise financial planning, Yuen secures the necessary capital to fuel innovation, ensuring the company remains well-positioned to meet the increasing demand for advanced neurovascular therapies in both domestic and international healthcare markets.

Sridhar Kosaraju, the Chief Financial Officer & Head of Strategy at Penumbra, architects the long-term business roadmap and strategic investment initiatives. Overseeing the integration of market intelligence with financial forecasting, the Chief Financial Officer & Head of Strategy identifies key growth vectors within the neurovascular and thrombectomy device sectors. This leadership role involves evaluating competitive landscapes to refine the company's product portfolio and market positioning. By aligning strategic goals with financial performance metrics, Sridhar Kosaraju drives the execution of expansion plans across global territories. The Chief Financial Officer & Head of Strategy collaborates with the executive team to prioritize R&D investments that yield high-impact clinical solutions. Through data-driven decision-making, Kosaraju ensures the company maintains a sustainable trajectory, balancing immediate operational needs with future-oriented innovation. This strategic oversight remains vital for navigating the evolving medical device landscape and achieving long-term value creation for stakeholders.

Lalit Panda, the Interim Chief Information Officer at Penumbra, directs the digital infrastructure and information security frameworks supporting global manufacturing operations. Overseeing the implementation of advanced data systems, the Interim Chief Information Officer ensures seamless connectivity across international facilities and supply chain networks. This leadership role involves modernizing IT architecture to enhance operational efficiency and data integrity for medical device development. By managing cybersecurity protocols, Lalit Panda protects critical intellectual property and patient-related data. The Interim Chief Information Officer collaborates with department heads to integrate digital tools that streamline production workflows and improve internal communication. Through the deployment of scalable technology solutions, Panda supports the company's ability to respond rapidly to market demands. This focus on robust information systems remains essential for maintaining the high standards of quality and compliance required in the medical device industry, ultimately facilitating the delivery of life-saving technologies to healthcare providers.

James Benenati, the Chief Medical Officer at Penumbra, leads the clinical strategy and medical oversight for the development of neurovascular and thrombectomy devices. Overseeing clinical trials and physician engagement programs, the Chief Medical Officer ensures that all product designs meet the rigorous safety and efficacy standards required for clinical adoption. This leadership role involves translating complex medical needs into actionable engineering requirements for the Neuron and 3D brand product lines. By fostering relationships with the global medical community, James Benenati drives the adoption of advanced therapies in hospitals and clinics. The Chief Medical Officer works with the research team to validate new technologies, ensuring that clinical outcomes remain the primary focus of innovation. Through expert medical guidance, Benenati supports the company's mission to improve patient care, ensuring that every device manufactured provides tangible benefits to clinicians and patients across international healthcare systems.